The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Urabe, Fumihiko; Kimura, Shoji; Iwatani, Kosuke; Yasue, Keiji; Koike, Yuhei; Tashiro, Kojiro; Tsuzuki, Shunsuke; Sasaki, Hiroshi; Kimura, Takahiro; Egawa, Shin

doi:10.3390/jcm10163692

Cited by 6 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of increased VTE risk in patients with a non-O blood type was reported in three previous meta-analyses, one including all cancer studies (including pediatric and leukemia patients), and the others including various patient populations. In these metaanalyses, non-O blood type was significantly associated with VTE, with ORs ranging from 1.74 to 2.09, [58][59][60] thereby closely aligning with our OR of 1.56. The magnitude of our association is slightly smaller than the other studies, but the significant heterogeneity observed in the other two meta-analyses provides evidence that the risk may vary in different patient populations.…”

Section: Discussionsupporting

confidence: 85%

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis

Roy,

Wang,

Lun

et al. 2024

American J Hematol

View full text Add to dashboard Cite

In the general population, individuals with an inherited thrombophilia have a higher risk of thrombosis, but the effect of inherited thrombophilia on the risk of cancer‐associated venous thromboembolism (VTE) remains controversial. Our objective was to determine the risk of VTE in cancer patients with inherited thrombophilia. We conducted a systematic review and meta‐analysis of studies reporting on VTE after a cancer diagnosis in adult patients who were tested for inherited thrombophilia. In September 2022, we searched Medline, EMBASE, and Cochrane Central. Two reviewers screened the abstracts/full texts and assessed study quality using the Quality in Prognostic Studies tool. We used Mantel–Haenszel random‐effects models to estimate pooled odds ratios (OR) of VTE and 95% confidence intervals (95%CI). We included 37 and 28 studies in the systematic review and meta‐analysis, respectively. Most studies focused on specific cancer types and hematologic malignancies were rare. The risk of VTE was significantly higher in cancer patients with non‐O (compared with O) blood types (OR: 1.56 [95% CI: 1.28–1.90]), Factor V Leiden, and Prothrombin Factor II G20210A mutations compared with wild types (OR: 2.28 [95% CI: 1.51–3.48] and 2.14 [95% CI: 1.14–4.03], respectively). Additionally, heterozygous and homozygous methylenetetrahydrofolate reductase C677T had ORs of 1.50 (95% CI: 1.00–2.24) and 1.38 (95% CI: 0.87–2.22), respectively. Among those with Plasminogen‐Activator Inhibitor‐1 4G/5G, Vascular Endothelial Growth Factor (VEGF) A C634G, and VEGF C2578A mutations, there was no significant association with VTE. In conclusion, this meta‐analysis provided evidence that non‐O blood types, Factor V Leiden, and Prothrombin Factor II G20210A mutations are important genetic risk factors for VTE in cancer patients.

show abstract

Section: Discussionsupporting

confidence: 85%

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis

Roy,

Wang,

Lun

et al. 2024

American J Hematol

View full text Add to dashboard Cite

show abstract

“…►Table 1 shows the major data extracted from the nine studies resulting from this search. Many of the studies 8,26,[28][29][30][31] highlight a positive association between non-O blood groups and VTE. Thrombotic events were either DVT or PE and almost all studies have reported elevated VWF levels in patients with non-O groups.…”

Section: Resultsmentioning

confidence: 99%

“…Finally, it will also be useful to investigate the impact of specific cancer types and patients' risk factors (e.g., tumor stage, tumor size, tumor site, obesity, chemotherapy) as the main drivers for increased risk in light of patients' ABO types. 29 These studies shall help assess the value of ABO as an added biomarker to improve the application of Khorana score or its modifications for better care of this patient cohort.…”

Section: Discussionmentioning

confidence: 99%

“…Overall, most published studies 8,26,[28][29][30][31] emphasized a positive association between non-O blood groups and thrombosis risk, with the remaining studies indicating a weak association or possibly possessing a significant number of limitations. 9,27,32 Future research is needed to establish a more definite conclusion of the impact of ABO group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review

Elsherif,

Zidan,

Saville

et al. 2023

Semin Thromb Hemost

View full text Add to dashboard Cite

Cancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized limitations. ABO blood groups are known to be implicated in hemostasis, in an association mediated through von Willebrand factor (VWF). In this narrative review, we aim to summarize the current knowledge surrounding the role of ABO blood groups in VTE, with a particular focus on the role of VWF and other contributing risk factors on VTE occurrence. We found evidence from literature for the impact of ABO blood groups in determining the risk of VTE in healthy populations, with a limited number of studies examining this effect in cancer patients. Additionally, research on the impact of ABO on different cancer types lacks rigor, particularly in regard to other risk factors. Overall, most studies showed strong association of increased risk of VTE amongst cancer patients with non-O blood groups and increased VWF levels. This association was weaker in a few studies. Further research is needed before a solid conclusion can be made about the ABO or ABO-VWF-mediated hypercoagulability and VTE risk in various cancers. These studies will help determine if ABO typing can be an added biomarker to improve VTE risk assessment models in cancer patients.

show abstract

“…Schleef et al (37) showed that vWF levels in the O-group population ranged from 654 to 1,028 U/L, whereas in the non-O-group population, their vWF levels ranged from 900 to 1,390 U/L, with a mean level of 1,339 U/L. Plasma vWF and circulating factor VIII concentrations are approximately 25% higher in non-O patients than in O patients (38). vWF is a multimer of variable molecular weight secreted by endothelial cells and megakaryocytes (39).…”

Section: Discussionmentioning

confidence: 99%

Association Between ABO Blood Group and Venous Thromboembolism Risk in Patients With Peripherally Inserted Central Catheters: A Meta-analysis and Systematic Review

Zhang¹,

Peng²,

Lu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPrevious studies have evaluated the association between ABO blood group and venous thromboembolism (VTE) risk in patients with peripherally inserted central catheters (PICCs). However, it remains unclear whether ABO blood groups are associated with PICC-associated VTE risk. Therefore, we conducted a meta-analysis of related studies to elucidate the potential role of ABO blood group as a risk factor for PICC-associated VTE.MethodsAll detectable case–control and cohort studies comparing the role of ABO blood group as a risk factor for PICC-associated VTE were collected for this analysis by searching PubMed, Embase, CNKI, Web of Science, and Wanfang. We conducted a meta-analysis of the eligible studies and computed the summary risk estimates with random or fixed effects models.ResultsA total of four studies involving 7,804 patients were included. Meta-analysis of the studies showed that the risk of PICC-associated VTE was significantly higher in blood types A [odds ratio (OR)=1.54, 95% CI=1.17–2.03), p=0.002], B (OR=2.35, 95% CI=1.71–3.23, p<0.0001), and AB (OR=2.55, 95% CI=1.68–3.88, p<0.0001) and lower in blood types O (OR=0.58, 95% CI=0.45–0.74, p<0.0001). Subgroup analysis based on ethnicity demonstrated that blood type O may be a genetic protective factor for PICC-associated VTE in Asians. Among Caucasians, individuals with blood types B and AB have a higher risk of PICC-associated VTE. Blood types A, B, and AB are risk factors for PICC-associated VTE in Asians.ConclusionsBlood type O is associated with a decreased risk of PICC-associated VTE, especially in Asian populations. Moreover, blood types A, B, and AB are risk factors for PICC-associated VTE.

show abstract

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Cited by 6 publications

References 30 publications

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis

ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review

Association Between ABO Blood Group and Venous Thromboembolism Risk in Patients With Peripherally Inserted Central Catheters: A Meta-analysis and Systematic Review

Contact Info

Product

Resources

About